References
- Inotai A, Petrova G, Vitezic D, et al. Benefits of investment into modern medicines in Central–eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):71–79.
- Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD/EU. Paris/ EU,Brussels: OECD Publishing; 2018. [cited 2019 Apr 11]. Available from https://doi.org/10.1787/health_glance_eur-2018-en
- International Society for Pharmacoeconomics and Outcomes Research. ISPOR Warsaw 2019 Program. [cited 2019 May 16]. Available from: https://www.ispor.org/docs/default-source/events/warsaw-2019/ispor-warsaw-2019.pdf?sfvrsn=5246ae9_2.
- Inotai A, Csanádi M, Vitezic D, et al. Policy practices to maximise social benefit from biosimilars. J Bioequivalence Bioavailability. 2017;9:467–472.
- Kristensen FB, Lampe K, Chase D, et al. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European network for Health Technology Assessment, EUnetHTA. Int J Technol Assess Health Care. 2009;25:(S2):1–8.
- Kristensen FB, Lampe K, Wild C, et al. The HTA Core Model—10 years of developing an international framework to share multidimensional value assessment. Value Health. 2017;20(2):244–250.
- European network for Health Technology Assessment. EUnetHTA early dialogue consolidated procedure. [cited 2019 May 16]. Available from: http://eunethta.eu/outputs/eunethta-early-dialogue-consolidated-procedure.
- Jahnz-Różyk K, Kawalec P, Malinowski K, et al. Drug policy in Poland. Value Health Reg Issues. 2017;13:23–26.
- EUnetHTA POP (planned and ongoing projects) database. [cited 2019 Apr 11]. Available from: https://www.eunethta.eu/pop-database/.